Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.61 |
| ▸ | CCR3 | P51677 | 3/20 | 0.60 |
| ▸ | ACHE | P22303 | 3/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971088 | 0.84 | CCR3 (0.57) | CCR3ACHE | |
| SCHEMBL8971084 | 0.84 | CCR3 (0.57) | CCR3ACHE | |
| SCHEMBL9427625 | 0.83 | CCR3 (0.56) | CCR3ACHE | |
| SCHEMBL9427623 | 0.83 | CCR3 (0.56) | CCR3ACHE | |
| SCHEMBL5232218 | 0.81 | ACHE (0.52) | ADRA1DADRA1AADRA1BACHE | |
| SCHEMBL14641272 | 0.80 | ADRB2 (0.52) | ACHE | |
| SCHEMBL7441668 | 0.80 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BACHEOPRD1 | |
| SCHEMBL8667135 | 0.80 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BACHEOPRD1 | |
| SCHEMBL7441676 | 0.80 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BACHEOPRD1 | |
| SCHEMBL6957478 | 0.79 | ACHE (0.74) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480892-A | SIGMA RECEPTOR ANTAGONISTS; TREATMENT OF PHYSIOLOGICAL OR DRUG INDUCED PSYCHOSIS AND DYSKINESIA | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5356906-A | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1993022310-A1 | (N-PHTHALIMIDOALKYL)PIPERIDINES FOR THE TREATMENT OF PSYCHOSES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| WO-1991006297-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-05-16 | — | — | WO | disclosed |